Skip to main content
Premium Trial:

Request an Annual Quote

Synthetic Bio Firm GeneForge Files for Chapter 7 Bankruptcy

NEW YORK (GenomeWeb News) – Synthetic biology instrument firm GeneForge has declared Chapter 7 bankruptcy and will be liquidating its assets.

The firm filed its petition on Dec. 7 in US Bankruptcy Court, Western District of Washington, listing $435,541 in assets and $2.5 million in liabilities.

The company had been based in Redwood City, Calif., but moved to Gig Harbor, Wash., after it was sold last year. On its website GeneForge lists three instrument products, the Coliseum RNA and DNA synthesizer; GF 3900 High-throughput DNA synthesizer; and the GF Deprotection Module High-throughput DNA synthesizer.

The firm also sold consumables.

Its bankruptcy filing lists a single creditor holding secured claims, Midland American Bank, which is claiming $185,000. Creditors holding unsecured claims include Bruce Erickson, the founder of GeneForge, who claims $1.6 million, and Mike Bailey, its President and CEO, who claims $67,875.

Erickson sold GeneForge to Bailey a year ago. This past September, Erickson and others sued Bailey, his wife Candace Bailey, and GeneForge in the Superior Court of the State of California, County of San Mateo alleging breach of contract.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.